Stress, inflammation, and cellular vulnerability during early stages of affective disorders: Biomarker strategies and opportunities for prevention and intervention

Frontiers in Psychiatry

Volumn 5, Issue APR, 2014, Pages

  Walker, Adam J ^a,b   Kim, Yesul ^a,b   Blair Price, J ^a   Kale, Rajas P ^a,b   McGillivray, Jane A ^b   Berk, Michael ^b,c,d,e   Tye, Susannah J ^a,b,f  

^a MAYO CLINIC   (United States)

^b DEAKIN UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^e FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Biomarker; Bipolar; Cellular resilience; Depression; Inflammation; Plasticity; Prodrome; Stress

Indexed keywords

ALLOSTASIS; ALLOSTATIC LOAD; CELLULAR PARAMETERS; CELLULAR RESILIENCE; CELLULAR VULNERABILITY; COPING BEHAVIOR; EARLY INTERVENTION; EARLY LIFE STRESS; EMOTIONALITY; HUMAN; INFLAMMATION; LIFESTYLE MODIFICATION; MOOD DISORDER; NERVE CELL PLASTICITY; NEUROPROTECTION; PREVENTION AND CONTROL; PRODROMAL SYMPTOM; RELIABILITY; RISK ASSESSMENT; SHORT SURVEY; SIGNAL TRANSDUCTION; SOCIAL SUPPORT;

EID: 84901033130     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2014.00034     Document Type: Short Survey

References (113)

1. Madhusoodanan S. Preventive psychiatry: we are getting closer to fulfilling the promise of reducing mental illness. Ann Clin Psychiatry (2010) 22(4):217-8.
2. Skjelstad DV, Malt UF, Holte A. Symptoms and signs of the initial prodrome of bipolar disorder: a systematic review. J Affect Disord (2010) 126(1-2):1-13. doi: 10.1016/j.jad.2009.10.003.
3. Berk M, Hallam K, Lucas N, Hasty M, McNeil CA, Conus P, et al. Early intervention in bipolar disorders: opportunities and pitfalls. Med J Aust (2007) 187(7 Suppl):S11-4.
4. Egeland JA, Hostetter AM, Pauls DL, Sussex JN. Prodromal symptoms before onset of manic-depressive disorder suggested by first hospital admission histories. J Am Acad Child Adolesc Psychiatry (2000) 39(10):1245-52. doi:10.1097/00004583-200010000-00011.
5. Strakowski SM, DelBello MP, Zimmerman ME, Getz GE, Mills NP, Ret J, et al. Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. Am J Psychiatry (2002) 159(11):1841-7. doi:10.1176/appi.ajp.159.11.1841.
6. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry (2002) 59(10):921-8. doi:10.1001/archpsyc.59.10.921.
7. Amminger GP, Schafer MR, Klier CM, Slavik JM, Holzer I, Holub M, et al. Decreased nervonic acid levels in erythrocyte membranes predict psychosis in help-seeking ultra-high-risk individuals. Mol Psychiatry (2012) 17(12):1150-2. doi:10.1038/mp.2011.167.
8. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry (2010) 67(2):146-54. doi:10.1001/archgenpsychiatry.2009.192.
9. Bauer ME, Wieck A, Lopes RP, Teixeira AL, Grassi-Oliveira R. Interplay between neuroimmunoendocrine systems during post-traumatic stress disorder: a mini review. Neuroimmunomodulation (2010) 17(3):192-5. doi:10.1159/000258721.
10. Leopold K, Ritter P, Correll CU, Marx C, Ozgurdal S, Juckel G, et al. Risk constellations prior to the development of bipolar disorders: rationale of a new risk assessment tool. J Affect Disord (2012) 136(3):1000-10. doi:10.1016/j.jad.2011.06.043.
11. Luby JL, Navsaria N. Pediatric bipolar disorder: evidence for prodromal states and early markers. J Child Psychol Psychiatry (2010) 51(4):459-71. doi:10.1111/j.1469-7610.2010.02210.x.
12. Schultze-Lutter F, Schimmelmann BG, Klosterkotter J, Ruhrmann S. Comparing the prodrome of schizophrenia-spectrum psychoses and affective disorders with and without psychotic features. Schizophr Res (2012) 138(2-3):218-22. doi:10.1016/j.schres.2012.04.001.
13. Weissman MM, Wolk S, Goldstein RB, Moreau D, Adams P, Greenwald S, et al. Depressed adolescents grown up. JAMA (1999) 281(18):1707-13. doi:10.1001/jama.281.18.1707.
14. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev (2011) 35(3):804-17. doi:10.1016/j.neubiorev.2010.10.001.
15. Gama CS, Kunz M, Magalhaes PV, Kapczinski F. Staging and neuroprogression in bipolar disorder: a systematic review of the literature. Rev Bras Psiquiatr (2013) 35(1):70-4. doi:10.1016/j.rbp.2012.09.001.
16. Eley TC, Liang H, Plomin R, Sham P, Sterne A, Williamson R, et al. Parental familial vulnerability, family environment, and their interactions as predictors of depressive symptoms in adolescents. J Am Acad Child Adolesc Psychiatry (2004) 43(3):298-306. doi:10.1097/00004583-200403000-00011.
17. Klengel T, Binder EB. Gene x environment interactions in the prediction of response to antidepressant treatment. Int J Neuropsychopharmacol (2013) 16(3):701-11. doi:10.1017/S1461145712001459.
18. Klengel T, Mehta D, Anacker C, Rex-Haffner M, Pruessner JC, Pariante CM, et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci (2013) 16(1):33-41. doi:10.1038/nn.3275.
19. Berk M, Williams LJ, Jacka FN, O'Neil A, Pasco JA, Moylan S, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med (2013) 11:200. doi:10.1186/1741-7015-11-200.
20. Anda RF, Butchart A, Felitti VJ, Brown DW. Building a framework for global surveillance of the public health implications of adverse childhood experiences. Am J Prev Med (2010) 39(1):93-8. doi:10.1016/j.amepre.2010.03.015.
21. Ehlert U. Understanding the trans-generational consequences of prenatal stress. J Psychosom Res (2013) 75(4):297-8. doi:10.1016/j.jpsychores.2013.09.002.
22. Fries GR, Pfaffenseller B, Stertz L, Paz AV, Dargel AA, Kunz M, et al. Staging and neuroprogression in bipolar disorder. Curr Psychiatry Rep (2012) 14(6):667-75. doi:10.1007/s11920-012-0319-2.
23. Lai MC, Huang LT. Effects of early life stress on neuroendocrine and neurobehavior: mechanisms and implications. Pediatr Neonatol (2011) 52(3):122-9. doi:10.1016/j.pedneo.2011.03.008.
24. Aschbacher K, O'Donovan A, Wolkowitz OM, Dhabhar FS, Su Y, Epel E. Good stress, bad stress and oxidative stress: insights from anticipatory cortisol reactivity. Psychoneuroendocrinology (2013) 38(9):1698-708. doi:10.1016/j.psyneuen.2013.02.004.
25. Carpenter LL, Gawuga CE, Tyrka AR, Lee JK, Anderson GM, Price LH. Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology (2010) 35(13):2617-23. doi:10.1038/npp.2010.159.
26. Heim C, Newport DJ, Heit S, Graham YP, Wilcox M, Bonsall R, et al. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA (2000) 284(5):592-7. doi:10.1001/jama.284.5.592.
27. Stankiewicz AM, Swiergiel AH, Lisowski P. Epigenetics of stress adaptations in the brain. Brain Res Bull (2013) 98(0):76-92. doi:10.1016/j.brainresbull.2013.07.003.
28. Menke A, Klengel T, Rubel J, Bruckl T, Pfister H, Lucae S, et al. Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav (2013) 12(3):289-96. doi:10.1111/gbb.12026.
29. Howell BR, Sanchez MM. Understanding behavioral effects of early life stress using the reactive scope and allostatic load models. Dev Psychopathol (2011) 23(4):1001-16. doi:10.1017/S0954579411000460.
30. McEwen BS, Stellar E. Stress and the individual. Mechanisms leading to disease. Arch Intern Med (1993) 153(18):2093-101. doi:10.1001/archinte.153.18.2093.
31. Kapczinski F, Dias VV, Kauer-Sant'Anna M, Frey BN, Grassi-Oliveira R, Colom F, et al. Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother (2009) 9(7):957-66. doi:10.1586/ern.09.31.
32. Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes FA, Tramontina J, et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev (2008) 32(4):675-92. doi:10.1016/j.neubiorev.2007.10.005.
33. McEwen BS. Mood disorders and allostatic load. Biol Psychiatry (2003) 54(3):200-7. doi:10.1016/S0006-3223(03)00177-X.
34. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry (2013) 18(5):595-606. doi:10.1038/mp.2012.33.
35. Pasco JA, Jacka FN, Williams LJ, Henry MJ, Nicholson GC, Kotowicz MA, et al. Leptin in depressed women: cross-sectional and longitudinal data from an epidemiologic study. J Affect Disord (2008) 107(1-3):221-5. doi:10.1016/j.jad.2007.07.024.
36. Brietzke E, Kapczinski F, Grassi-Oliveira R, Grande I, Vieta E, McIntyre RS. Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev Neurother (2011) 11(7):1017-28. doi:10.1586/ern.10.185.
37. Gallo LC, Shivpuri S, Gonzalez P, Fortmann AL, de los Monteros KE, Roesch SC, et al. Socioeconomic status and stress in Mexican-American women: a multi-method perspective. J Behav Med (2013) 36(4):379-88. doi:10.1007/s10865-012-9432-2.
38. Grande I, Magalhaes PV, Kunz M, Vieta E, Kapczinski F. Mediators of allostasis and systemic toxicity in bipolar disorder. Physiol Behav (2012) 106(1):46-50. doi:10.1016/j.physbeh.2011.10.029.
39. Naviaux RK. Metabolic features of the cell danger response. Mitochondrion (2013). doi:10.1016/j.mito.2013.08.006.
40. Wang YM, Liu XD, Zhang DF, Chen JH, Liu SZ, Berk M. The effects of apoptosis vulnerability markers on the myocardium in depression after myocardial infarction. BMC Med (2013) 11:32. doi:10.1186/1741-7015-11-32.
41. Brietzke E, Kapczinski F. TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry (2008) 32(6):1355-61. doi:10.1016/j.pnpbp.2008.01.006.
42. Tye SJ. Allostatic overload: transcriptomic insights into the molecular basis of antidepressant resistance. Bipolar Disord (2013) 15(s1):1-163.
43. Walker AJ, Burnett SA, Hasebe K, McGillivray JA, Gray LJ, McGee SL, et al. Chronic adrenocorticotropic hormone treatment alters tricyclic antidepressant efficacy and prefrontal monoamine tissue levels. Behav Brain Res (2013) 242:76-83. doi:10.1016/j.bbr.2012.12.033.
44. Almeida OP, Flicker L, Yeap BB, Alfonso H, McCaul K, Hankey GJ. Aspirin decreases the risk of depression in older men with high plasma homocysteine. Transl Psychiatry (2012):2. doi:10.1038/tp.2012.79.
45. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry (2009) 70(8):1078-90. doi:10.4088/JCP.08r04505.
46. Padmos RC, Van Baal GC, Vonk R, Wijkhuijs AJ, Kahn RS, Nolen WA, et al. Genetic and environmental influences on pro-inflammatory monocytes in bipolar disorder: a twin study. Arch Gen Psychiatry (2009) 66(9):957-65. doi:10.1001/archgenpsychiatry.2009.116.
47. Danese A, Pariante CM, Caspi A, Taylor A, Poulton R. Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad Sci U S A (2007) 104(4):1319-24. doi:10.1073/pnas.0610362104.
48. Maes M, Berk M, Goehler L, Song C, Anderson G, Galecki P, et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med (2012) 10:66. doi:10.1186/1741-7015-10-66.
49. Slopen N, Kubzansky LD, McLaughlin KA, Koenen KC. Childhood adversity and inflammatory processes in youth: a prospective study. Psychoneuroendocrinology (2013) 38(2):188-200. doi:10.1016/j.psyneuen.2012.05.013.
50. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun (2007) 21(2):153-60. doi:10.1016/j.bbi.2006.09.006.
51. Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun (2011) 25(2):181-213. doi:10.1016/j.bbi.2010.10.015.
52. Liukkonen T, Silvennoinen-Kassinen S, Jokelainen J, Rasanen P, Leinonen M, Meyer-Rochow VB, et al. The association between C-reactive protein levels and depression: results from the northern Finland 1966 birth Cohort study. Biol Psychiatry (2006) 60(8):825-30. doi:10.1016/j.biopsych.2006.02.016.
53. Mills NT, Scott JG, Wray NR, Cohen-Woods S, Baune BT. Research review: the role of cytokines in depression in adolescents: a systematic review. J Child Psychol Psychiatry (2013) 54(8):816-35. doi:10.1111/jcpp.12080.
54. Gabbay V, Klein RG, Alonso CM, Babb JS, Nishawala M, De Jesus G, et al. Immune system dysregulation in adolescent major depressive disorder. J Affect Disord (2009) 115(1-2):177-82. doi:10.1016/j.jad.2008.07.022.
55. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol (2009) 12(4):447-58. doi:10.1017/S1461145708009310.
56. Pasco JA, Nicholson GC, Williams LJ, Jacka FN, Henry MJ, Kotowicz MA, et al. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry (2010) 197(5):372-7. doi:10.1192/bjp.bp.109.076430.
57. Biesmans S, Meert TF, Bouwknecht JA, Acton PD, Davoodi N, De Haes P, et al. Systemic immune activation leads to neuroinflammation and sickness behavior in mice. Mediators Inflamm (2013) 2013:271359. doi:10.1155/2013/271359.
58. Erhardt S, Olsson SK, Engberg G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs (2009) 23(2):91-101. doi:10.2165/00023210-200923020-00001.
59. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry (2005) 29(2):201-17. doi:10.1016/j.pnpbp.2004.11.003.
60. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci (2012) 13(7):465-77. doi:10.1038/nrn3257.
61. Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation (2011) 8:94. doi:10.1186/1742-2094-8-94.
62. Pandey GN, Rizavi HS, Ren X, Fareed J, Hoppensteadt DA, Roberts RC, et al. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res (2012) 46(1):57-63. doi:10.1016/j.jpsychires.2011.08.006.
63. Falcone T, Carlton E, Lee C, Janigro M, Fazio V, Forcen FE, et al. Does systemic inflammation play a role in pediatric psychosis? Clin Schizophr Relat Psychoses (2013) 1-43. doi:10.3371/CSRP.FACA.030813.
64. Byrne ML, O'Brien-Simpson NM, Reynolds EC, Walsh KA, Laughton K, Waloszek JM, et al. Acute phase protein and cytokine levels in serum and saliva: a comparison of detectable levels and correlations in a depressed and healthy adolescent sample. Brain Behav Immun (2013) 34:164-75. doi:10.1016/j.bbi.2013.08.010.
65. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science (2012) 338(6103):68-72. doi:10.1126/science.1222939.
66. Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci (2012) 35(1):47-56. doi:10.1016/j.tins.2011.11.004.
67. Mesulam MM. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron (1999) 24(3):521-9. doi:10.1016/S0896-6273(00)81109-5.
68. Zarate CA Jr, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry (2006) 59(11):1006-20. doi:10.1016/j.biopsych.2005.10.021.
69. Drevets WC. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol (2001) 11(2):240-9. doi:10.1016/S0959-4388(00)00203-8.
70. D'Sa C, Duman RS. Antidepressants and neuroplasticity. Bipolar Disord (2002) 4(3):183-94. doi:10.1034/j.1399-5618.2002.01203.x.
71. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron (2002) 34(1):13-25. doi:10.1016/S0896-6273(02)00653-0.
72. Young LT. Neuroprotective effects of antidepressant and mood stabilizing drugs. J Psychiatry Neurosci (2002) 27(1):8-9.
73. Collingridge GL, Peineau S, Howland JG, Wang YT. Long-term depression in the CNS. Nat Rev Neurosci (2010) 11(7):459-73. doi:10.1038/nrn2867.
74. Li X, Jope RS. Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology (2010) 35(11):2143-54. doi:10.1038/npp.2010.105.
75. Gould TD, Manji HK. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology (2005) 30(7):1223-37. doi:10.1038/sj.npp.1300731.
76. Machado-Vieira R, Soeiro-De-Souza MG, Richards EM, Teixeira AL, Zarate CA Jr. Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach. World J Biol Psychiatry (2013). doi:10.3109/15622975.2013.830775.
77. Baek JH, Bernstein EE, Nierenberg AA. One-carbon metabolism and bipolar disorder. Aust N Z J Psychiatry (2013) 47(11):1013-8. doi:10.1177/0004867413502091.
78. Nierenberg AA, Kansky C, Brennan BP, Shelton RC, Perlis R, Iosifescu DV. Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development. Aust N Z J Psychiatry (2013) 47(1):26-42. doi:10.1177/0004867412449303.
79. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature (2008) 455(7215):894-902. doi:10.1038/nature07455.
80. McKernan DP, Dinan TG, Cryan JF. "Killing the blues": a role for cellular suicide (apoptosis) in depression and the antidepressant response? Prog Neurobiol (2009) 88(4):246-63. doi:10.1016/j.pneurobio.2009.04.006.
81. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol (2000) 1(2):120-9. doi:10.1038/35040009.
82. Earnshaw WC. Apoptosis. A cellular poison cupboard. Nature (1999) 397(6718):387-9. doi:10.1038/17015.
83. Dodd S, Maes M, Anderson G, Dean OM, Moylan S, Berk M. Putative neuroprotective agents in neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry (2013) 42:135-45. doi:10.1016/j.pnpbp.2012.11.007.
84. Herberth M, Koethe D, Levin Y, Schwarz E, Krzyszton ND, Schoeffmann S, et al. Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival. Proteomics (2011) 11(1):94-105. doi:10.1002/pmic.201000291.
85. Maes M, Fisar Z, Medina M, Scapagnini G, Nowak G, Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology (2012) 20(3):127-50. doi:10.1007/s10787-011-0111-7.
86. Davidson RJ, McEwen BS. Social influences on neuroplasticity: stress and interventions to promote well-being. Nat Neurosci (2012) 15(5):689-95. doi:10.1038/nn.3093.
87. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry (1996) 153(2):151-62.
88. McGorry PD. Truth and reality in early intervention. Aust N Z J Psychiatry (2012) 46(4):313-6. doi:10.1177/0004867412442172.
89. van der Gaag M, Smit F, Bechdolf A, French P, Linszen DH, Yung AR, et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res (2013) 149(1-3):56-62. doi:10.1016/j.schres.2013.07.004.
90. Berk M, Conus P, Kapczinski F, Andreazza AC, Yucel M, Wood SJ, et al. From neuroprogression to neuroprotection: implications for clinical care. Med J Aust (2010) 193(4 Suppl):S36-40.
91. Kessing LV, Hansen HV, Christensen EM, Dam H, Gluud C, Wetterslev J. Do young adults with bipolar disorder benefit from early intervention? J Affect Disord. doi:10.1016/j.jad.2013.10.001.
92. Hansen HV, Christensen EM, Dam H, Gluud C, Wetterslev J, Kessing LV. The effects of centralised and specialised intervention in the early course of severe unipolar depressive disorder: a randomised clinical trial. PLoS One (2012) 7(3):e32950. doi:10.1371/journal.pone.0032950.
93. Clarke GN, Hornbrook M, Lynch F, Polen M, Gale J, Beardslee W, et al. A randomized trial of a group cognitive intervention for preventing depression in adolescent offspring of depressed parents. Arch Gen Psychiatry (2001) 58(12):1127-34. doi:10.1001/archpsyc.58.12.1127.
94. Harrington R, Rutter M, Fombonne E. Developmental pathways in depression: multiple meanings, antecedents, and endpoints. Dev Psychopathol (1996) 8:610-6. doi:10.1017/S095457940000732X.
95. Kuo ES, Vander Stoep A, Herting JR, Grupp K, McCauley E. How to identify students for school-based depression intervention: can school record review be substituted for universal depression screening? J Child Adolesc Psychiatr Nurs (2013) 26(1):42-52. doi:10.1111/jcap.12010.
96. Conus P, Ward J, Hallam KT, Lucas N, Macneil C, McGorry PD, et al. The proximal prodrome to first episode mania-a new target for early intervention. Bipolar Disord (2008) 10(5):555-65. doi:10.1111/j.1399-5618.2008.00610.x.
97. Berk M, Sarris J, Coulson CE, Jacka FN. Lifestyle management of unipolar depression. Acta Psychiatr Scand Suppl (2013) 127(Suppl 443):38-54. doi:10.1111/acps.12124.
98. Karatsoreos IN, McEwen BS. Resilience and vulnerability: a neurobiological perspective. F1000Prime Rep (2013) 5:13.
99. Mathew A, Nanoo S. Psychosocial stressors and patterns of coping in adolescent suicide attempters. Indian J Psychol Med (2013) 35(1):39-46. doi:10.4103/0253-7176.112200.
100. Segerstrom SC, Taylor SE, Kemeny ME, Fahey JL. Optimism is associated with mood, coping, and immune change in response to stress. J Pers Soc Psychol (1998) 74(6):1646-55. doi:10.1037/0022-3514.74.6.1646.
101. Wadee AA, Kuschke RH, Kometz S, Berk M. Personality factors, stress and immunity. Stress Health (2001) 17(1):25-40. doi:10.1002/1532-2998(200101)17:1<25::AID-SMI873>3.0.CO;2-N.
102. Giltay EJ, Zitman FG, Kromhout D. Dispositional optimism and the risk of depressive symptoms during 15 years of follow-up: the Zutphen Elderly Study. J Affect Disord (2006) 91(1):45-52. doi:10.1016/j.jad.2005.12.027.
103. Adler NE. Health disparities: what's optimism got to do with it? J Adolesc Health (2007) 40(2):106-7. doi:10.1016/j.jadohealth.2006.12.003.
104. Jorm AF. Mental health literacy: empowering the community to take action for better mental health. Am Psychol (2012) 67(3):231-43. doi:10.1037/a0025957.
105. Steptoe A, Wardle J, Pollard TM, Canaan L, Davies GJ. Stress, social support and health-related behavior: a study of smoking, alcohol consumption and physical exercise. J Psychosom Res (1996) 41(2):171-80. doi:10.1016/0022-3999(96)00095-5.
106. Motl RW, Birnbaum AS, Kubik MY, Dishman RK. Naturally occurring changes in physical activity are inversely related to depressive symptoms during early adolescence. Psychosom Med (2004) 66(3):336-42. doi:10.1097/01.psy.0000126205.35683.0a.
107. Jacka FN, Pasco JA, Williams LJ, Leslie ER, Dodd S, Nicholson GC, et al. Lower levels of physical activity in childhood associated with adult depression. J Sci Med Sport (2011) 14(3):222-6. doi:10.1016/j.jsams.2010.10.458.
108. Moylan S, Eyre HA, Maes M, Baune BT, Jacka FN, Berk M. Exercising the worry away: how inflammation, oxidative and nitrogen stress mediates the beneficial effect of physical activity on anxiety disorder symptoms and behaviours. Neurosci Biobehav Rev (2013) 37(4):573-84. doi:10.1016/j.neubiorev.2013.02.003.
109. Garner AS, ShonkoffJP. Early childhood adversity, toxic stress, and the role of the pediatrician: translating developmental science into lifelong health. Pediatrics (2012) 129(1):e224-31. doi:10.1542/peds.2011-2662.
110. Jacka FN, Kremer PJ, Berk M, de Silva-Sanigorski AM, Moodie M, Leslie ER, et al. A prospective study of diet quality and mental health in adolescents. PLoS One (2011) 6(9):e24805. doi:10.1371/journal.pone.0024805.
111. Jacka FN, Ystrom E, Brantsaeter AL, Karevold E, Roth C, Haugen M, et al. Maternal and early postnatal nutrition and mental health of offspring by age 5 years: a prospective cohort study. J Am Acad Child Adolesc Psychiatry (2013) 52(10):1038-47. doi:10.1016/j.jaac.2013.07.002.
112. Moylan S, Gustavson K, Karevold E, Overland S, Jacka FN, Pasco JA, et al. The impact of smoking in adolescence on early adult anxiety symptoms and the relationship between infant vulnerability factors for anxiety and early adult anxiety symptoms: the TOPP Study. PLoS One (2013) 8(5):e63252. doi:10.1371/journal.pone.0063252.
113. Moylan S, Jacka FN, Pasco JA, Berk M. How cigarette smoking may increase the risk of anxiety symptoms and anxiety disorders: a critical review of biological pathways. Brain Behav (2013) 3(3):302-26. doi:10.1002/brb3.137.